Lastly, TRM rely on fatty acid metabolism, facilitated by the gene FABP5 and its upstream regulator, PPARG, to survive and persist in nutrient-deficient barrier sites (41), and these genes were enriched in CD8+ T cells in patients with CLAD-BOS (Figure 2B). This evidence concerns the gene PPARG and Buschke-Ollendorff syndrome.